Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients

Genitourinary Medicine

Volumn 72, Issue 4, 1996, Pages 237-246

  Heylen, Rachel ^a   Miller, Robert ^b,c  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; CIDOFOVIR; CLARITHROMYCIN; DIDANOSINE; FLUCONAZOLE; FLUCYTOSINE; FOSCARNET; GANCICLOVIR; ITRACONAZOLE; KETOCONAZOLE; PROBENECID; RIFABUTIN; RIFAMPICIN; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADVERSE DRUG REACTION; DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW;

EID: 79960418180     PISSN: 02664348     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.72.4.237     Document Type: Review

References (72)

1. Blum MR, Liao SH, Good SS, de Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988 85: (suppl 2A) 189-4.
2. ABPI Data Sheet Compendium 1995-96:326-8. Videx.
3. ABPI Data Sheet Compendium 1995-96:1431-3. 1431-3. Hivid.
4. Dudley M, Graham K, Kaul S, et al. Pharrnacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis 1992;166:480-5.
5. ABPI Data Sheet Compendium 1995-96:1952-6. Retrovir
6. Fischl MA, Richman DD, Grieco MH, a al. The efficacy of azidothymidine (zidovudine) in the treatment of patients with AIDS and AIDS related complex. A double blind placebo-controlled trial. N Engl J Med 1987;317-185-91.
7. Shriner K, Bidwell Goetz M. Severe hepatotoxicity in a patient receiving both acetaminophen and zidovudine. Am J Med 1992;93:94-6.
8. Steffe EM, King JH, Inciardi JF, et al. The effect of acetaminophen on zidovudine metabolism in HIV-infected patients. J Acquir Immun Def Synd 1990;3:691-4.
9. Burger DM, Meenhorst PL, Koks CHW, Beijnen JH. Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy. Ann Pharmacother 1994;28:327-30.
10. Craft MS, Craft JC. Drug interaction between clarithromycin and oral zidovudine in HIV-1 infected patients. Clin Pharmacol Ther 1994;53:163.1-114.
11. Vance E, Watson-Bitar M, Gustavson L, Kazanjian P. Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. Antimicrob Agents Chemother 1995;39:1355-60.
12. Schwanz EL, Brechbuhl AB, Kahl P, Miller MA, Selwyn PA, Friedland GH. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. J Acquir Immun Def Synd 1992;5:619-26.
13. Asgari M, Back DJ. Effect of azoles on the glucuronidation of zidovudine by human liver UDP-glucuronosyltransferase. J Infect Dis 1995;172:1634-6.
14. Hansten PD, Horn JR. Drug Interactions and Updates. Vancouver, Applied Therapeutics Inc. 1990.
15. Jones M, Bristol-Myers Squibb Pharmaceuticals Ltd: Personal communication, didanosine and probenecid.
16. Narang P, Nightingale S, Manzone C, et al. Does rifabutin affect zidovudine disposition in HIV + ve patients ? VIII International Conference on AIDS, III STD World Congress July 1992; Abstract PoB 3888.
17. Gaines K, Wong R, Jung D, et al. Pharmacokinetic interactions with oral ganciclovir: zidovudine, didanosine, probenecid. 10th International Conference on AIDS: 1994 Aug 7-12; Yokohama Qapan) 1994 Abstract 004B.
18. Personal communication Syntex Pharmaceuticals Ltd didanosine and ganciclovir.
19. Metroka CE, McMechan MF, Andrada R, Laubenstein LJ, Jacobus DP. Failure of prophylaxis with dapsone in patients taking dideoxyinosine. N Engl J Med 1991;325:737.
20. Hochster H, Dieterich D, Bozette S, et al. Toxicity of Combined ganciclovir and zidovudine for cytomegalo-virus disease associated with AIDS. Ann Int Med 1990;113:111-7.
21. Palestine AG, Polis MA, De Smet MD, et al. A randomised, controlled trial of foscarnet in the treatment of cytomegalovirus retinirus in patients with AIDS. Ann Int Med 1991;115:665-73.
22. NIAID updates dideoxyinosine toxicity profile, suggests ways to reduce risk of pancreatitis. Clinical Pharmacy 1990;9:832-8.
23. Bach MC. Possible drug interaction during therapy with azidothymidine and acyclovir for AIDS. N Engl J Med 1987;316:547.
24. Israelski DM, Corrynne T, Remington JS. Zidovudine antagonises the action of pyrimethamine in experimental infection with Toxoplasma gondii. Antimicrob Agents Chemother 1989;33:30-4.
25. Sandstrom E, Oberg B. Antiviral therapy in human immunodeficiency virus infections. Current status (part 1). Drugs 1993;45:488-508.
26. Medina DJ, Hsiung GD, Mellors JW. Ganciclovir antagonises the anti-human immunodeficiency virus type activity of zidovudine and didanosine in vitro. Antimicrob Agents Chemother 1992;36:2217-30.
27. Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulphamethoxazole to treat PCP in patients with AIDS. New Engl J Med 1993;328:1521-7.
28. Seaton TL, Celum CL, Black DJ. Possible potentiation of warfarin by fluconazole. DICP. Ann Pharmacother 1990;24:1177-8.
29. Honig PK, Wortham DC, Hull R, Zamani K, Smith JE, Cantilena LR. Itraconzole affects single-dose terfenadine Pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 1993;33:1201-6.
30. Bohme A, Ganser A, Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Haematol 1995;71:311-2.
31. Olkkola KT, et al. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-5.
32. Committee on Safety of Medicines. Medicines Control Agency. Curr Probl Pharmacovigil 1996;22:1-2.
33. Cadle RM, Zenon GJ, Rodriguez-Barradas MC, Hamill RJ. Fluconazole induced symptomatic phenytoin toxicity. Ann Pharmacother 1994;28:191-5.
34. Blomley M, Teare EL, de Belder A, Thway Y, Weston M. Itraconazole and anti-tuberculosis drugs. Lancet 1990;336:1255.
35. Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampicin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis 1994;18:266.
36. Nicolau DP, Crowe HM, Nightingale CH, Quintiliani R. Rifampicin-fluconazole interaction in critically ill patients. Ann Pharmacother 1995;29:994-6.
37. Coker RJ, Tomlinson DR, Parkin J, Harris JRW, Pinching AJ. Interaction between fluconazole and rifampicin. BMJ 1990;301:818.
38. Bonay M, Jonville-Bera AP, Diot P, Lemarie E, Lavandier M, Autret E. Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Safety 1993:9-309-11.
39. ABPI Data Sheet Compendium 1995-96:7.34-5. Nizoral.
40. Blum RA, D'Andrea DT, Florentine BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991;114:755-7.
41. Sugar EF, Sugar AM, Kreger BE. Effect of common beverages on the dissolution of ketoconazole tablets. AIDS 1992;6:1221-2.
42. Antoniskis D, Larsen RA. Acute progressive renal failure with the simultaneous use of amphotericin B and pentamidine. Antimicrob Agents Chemother 1990;34:470-2.
43. ABPI Data Sheet Compendium 1995-6:1774 Fungizone intravenous.
44. Pahls S, Schaffner A. Aspergillus fumigatus pneumonia in neutropenic patients receiving fluconazole for infection due to Candida species: is amphotericin B combined with fluconazole the appropriate answer? Clin Infect Dis 1994;18:484-5.
45. Scheven M, Scheven ML. Interaction between azoles and amphotericin B in the treatment of candidiasis. Clin Infect Dis 1995;20:1079.
46. Buffington GA, Dominguez JH, Piering WF, et al. Interaction of rifampicin and glucorticoids. JAMA 1976;236:1958-60.
47. Horowitz HW, Jorde UP, Wormser GP. Drug interactions in use of dapsone for Pneumocystis carinii prophylaxis. Lancet 1992;339:747.
48. Wagner JC. Rifampicin-Phenytoin drug interaction. Drug Intell Clin Pharm 1984;18:497[Abstract].
49. ABPI Data Sheet Compendium 1995-6:950-2. Rifadin.
50. Jacobson M, Yajko D, Nothfelt D, et al. Randomised placebo controlled trial of rifampicin, ethambutol, and ciprofloxadn for AIDS patients with disseminated MAC infection. J Infect Dis 1993;168:112-9.
51. Wallace RJ, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampicin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995;171:747-50.
52. Griffith DE, Brown BA, Girard WM, Wallace RJ. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995;21:594-8.
53. Siegal FP, Eilbott D, Burger H, et al. Dose-limiting toxicity of rifabutin in AIDS-related complex: syndrome of arthralgia/arthritis. AIDS. 1990;4:433-41.
54. Rifabutin prophylaxis against Mycobacterium avium complex infection. New Engl J Med 1994;330:436-39.
55. Misc authors. Comments on Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993;329:828-33.
56. Frank MO, Graham MB, Wispelway B. Rifabutin and uveitis. N Engl J Med 1994;330:868.
57. Fuller JD, Stanfield LED, Craven DE. Rifabutin prophylaxis and uveitis. N Eng J Med 1994;330:1315-6.
58. Narang PK, Trapnell CB, Schoenfelder JR, Lavelle JP, Bianchine JR. Fluconazole and enhanced effect of rifabutin prophylaxis. N Engl J Med 1994;330:1316.
59. Ballow C, Amsden GW. Azithromycin: The first azalide antibiotic. Ann Pharmacother 1992;26:1253-61.
60. Pensayre D, Larrey D, Funck-Brentano C, Benhamen JP. Drug interaction and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother 1985;16:(Suppl A):181-94.
61. Albani F, Riva R, Barmzzi A, et al. Clarithromycin-carbamazepine interaction: a case report. Epilepsia 1993;34:161-2.
62. Hansten P, Horn JR. Drug interactions with non-sedating antihistamines. Drug Interactions Newsletter 1994:737-40.
63. ABPI Data Sheet Compendium 1995-6:15-6. Klaricid.
64. Tobe SW, Sui LL, Jamal SA, et al. Vinblastine and erythromycin: an unrecognised serious drug interaction. Cancer Chemother Pharmacol 1995;35:188-90.
65. Yonren S. Phase 1 study to evaluate the pharmacokinetic interaction between rifabutin and the macrolides azithromycin and clarithromycin in healthy subjects. (066-074) Personnal communication 26.9.95.
66. Caplin M, Thompson N, Hamilton M, McIntyre N, Burroughs A. Antituberculous therapy and acute liver failure. Lancet 1995;345:1171.
67. de Miranda P, Blium MR. Pharmacokinetics of aciclovir after intravenous and oral administration. J Antimicrob Chemother 1983; (Suppl B):29-37.
68. Jacobson M, de Miranda P, Cederberg DM, et al. Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob Agents Chemother 1987;31:1251-4.
69. Byrne AK, Lavelle J, Follensbee S, et al. Multiple dose cross over pharmacokinetic study to evaluate the effect of food on the relative bioavailability of oral ganciclovir (abstract no. PuB 7077). Proceedings of the VIII International Conference on AIDS and the III STD World Congress; 1992 Jul 19-24: Amsterdam.
70. Sjovall J, Bergdahl S, Movin G, Ogenstad S, Saarimaki M. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with HIV. Antimicrob Agents Chemother 1989;33:1023-31.
71. Cundy K, Petty BG, Flaherty J, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1995;39:1247-52.
72. Fan-Harvard P, Sanchorawala V, Oh J, Moser EM, Smith SP. Concurrent use of foscarnet and ciprofloxacin may increase the propensitity for seizures. Ann Pharmacother 1994;28:869-72.